Oral Presentation
Chairs: C. Lange (Borstel, Germany), M. Amicosante (Rome, Italy)

Tuberculosis associated with anti-TNF_α treatment: series of 9 clinical cases A. Croitoru, D. Bumbacea, M. Lazar, K. Serban, C. Tudose, C. Toma, S. Dumitrache-Rujinski, M. Bogdan (Bucharest, Romania)
Does anti TNF-α treatment increase tuberculosis risk? B. Musellim, F. Zuhur, G. Ongen, I. Ozdemir, S. Erturan, G. Hatemi, V. Hamuryudan (Istanbul, Turkey)
Tumor necrosis factor alpha inhibitors and reactivation of tuberculosis A. Yalcin, N. Demir, O. Kayacan (Ankara, Turkey)
Isoniazid protection and risk of tuberculosis in patients who used anti tumor necrosis factor-alpha treatment O. Elbek, S. Borekci, M. Uyar, N. Bayram, H. Bayram, O. Dikensoy (Gaziantep, Turkey)
Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients Y. Kobashi, K. Mouri, Y. Obase, N. Miyashita, M. Oka (Kurashiki, Japan)
One year follow-up of T-SPOT. TB results in treated patients with active tuberculosis A. Bossink, S. Thijsen, J. Bouwman (Utrecht, Netherlands)
*Massive expansion of PPD-reactive CD4 T cells directed against a single peptide epitope from the M. tuberculosis* ESAT-6 protein** T. Hodapp, U. Mack, U. Sester, H. Köhler, G. W. Sybrecht, M. Sester (Homburg, Germany)
Comparison of effector T-cell responses in patients with active TB disease compared to latent TB infection F. Piana, R. Baldan, L. R. Codecasa, G. B. Migliori, M. Ferrarese, D. M. Cirillo (Milan, Tradate, Italy)